Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009–2015

Choi, Suk Joo; Park, Ki Sup; Kim, Yae-Jean

doi:10.1016/j.jiac.2019.02.013

Cited by 6 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 23 Moreover, these RSV-specific monoclonal antibodies can potentially exert selective pressure after their widespread use in clinical practice, even though their prevalence is currently extremely low. In a study analyzing the F gene of RSV samples collected from 2009 to 2015 in Korea, Choi et al 13 reported the prevalence of the N201S substitution (16.7%), which reduced the neutralization capacity of nirsevimab. Therefore, continuous monitoring of RSV genotypes at the national level is imperative.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Genotype Analysis of Respiratory Syncytial Virus Before and After the COVID-19 Pandemic Using Whole-Genome Sequencing: A Prospective, Single-Center Study in Korea From 2019 to 2022

Na,

Park,

Seo

et al. 2024

J Korean Med Sci

View full text Add to dashboard Cite

Background Respiratory syncytial virus (RSV), a highly transmissible virus, is the leading cause of lower respiratory tract infections. We examined molecular changes in the RSV genome before and after the coronavirus disease 2019 (COVID-19) pandemic in Korea, and investigated whether drug-resistant mutations were present. Methods In this prospective, single-center study, RSV-positive respiratory samples were collected between September 2019 and December 2022. Long-read whole-genome sequencing (WGS) was performed, and the presence of known drug-resistant substitutions for palivizumab, nirsevimab, and suptavumab was investigated. Results Overall, 288 respiratory samples were collected from 276 children. WGS data were available for 133 samples (71 and 62 samples from the pre- and post-pandemic periods, respectively). All RSV-A strains (n = 56) belonged to the GA2.3.5 (ON1) genotype, whereas all RSV-B strains (n = 77) belonged to the GB5.0.5a (BA) genotype. No significant differences in genotypes were observed between the pre- and post-pandemic periods. In addition, no notable mutations related to nirsevimab or palivizumab resistance were detected in the F gene. However, the L172Q and S173L substitutions, which are known to confer resistance to suptavumab, were present in all RSV-B samples. Conclusion Despite the unprecedented interruption of RSV seasonality, there were no significant molecular changes in circulating RSV strains in Korea related to nirsevimab or palivizumab resistance before and after the COVID-19 pandemic. However, RSV-specific drug-resistance substitutions for suptavumab were identified.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Furthermore, regarding the F gene, we investigated the presence of known substitutions against currently approved or in-development RSV-specific monoclonal antibodies. 13 14 The RSV genomic data analyzed in this study has been deposited in NCBI GenBank (PP785426-PP785558).…”

Section: Methodsmentioning

confidence: 99%

Genotype Analysis of Respiratory Syncytial Virus Before and After the COVID-19 Pandemic Using Whole-Genome Sequencing: A Prospective, Single-Center Study in Korea From 2019 to 2022

Na,

Park,

Seo

et al. 2024

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…Of the 233 subjects administered therapy, 18 developed resistance. 117 Discouragingly, certain resistance-associated mutations in F, such as V127A, were already present in a subset of subjects and had previously been documented to be circulating in South Africa, 118 Korea, 119 and Buenos Aires 12 , 120 at varying frequencies. Likewise, the proposed monoclonal antibody therapeutic suptavumab failed a randomized, double-blind, placebo-controlled phase 3 trial due to the emergence of RSV-B strains with L172Q and S173 L mutations in F that decreased the binding affinity of the antibody.…”

Section: Introductionmentioning

confidence: 99%

Clinical and biological consequences of respiratory syncytial virus genetic diversity

Guzman

Hultquist

2022

Therapeutic Advances in Infection

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is one of the most common etiological agents of global acute respiratory tract infections with a disproportionate burden among infants, individuals over the age of 65, and immunocompromised populations. The two major subtypes of RSV (A and B) co-circulate with a predominance of either group during different epidemic seasons, with frequently emerging genotypes due to RSV’s high genetic variability. Global surveillance systems have improved our understanding of seasonality, disease burden, and genomic evolution of RSV through genotyping by sequencing of attachment (G) glycoprotein. However, the integration of these systems into international infrastructures is in its infancy, resulting in a relatively low number (~2200) of publicly available RSV genomes. These limitations in surveillance hinder our ability to contextualize RSV evolution past current canonical attachment glycoprotein (G)-oriented understanding, thus resulting in gaps in understanding of how genetic diversity can play a role in clinical outcome, therapeutic efficacy, and the host immune response. Furthermore, utilizing emerging RSV genotype information from surveillance and testing the impact of viral evolution using molecular techniques allows us to establish causation between the clinical and biological consequences of arising genotypes, which subsequently aids in informed vaccine design and future vaccination strategy. In this review, we aim to discuss the findings from current molecular surveillance efforts and the gaps in knowledge surrounding the consequence of RSV genetic diversity on disease severity, therapeutic efficacy, and RSV–host interactions.

show abstract

Genomic characterization of human respiratory syncytial virus circulating in Islamabad, Pakistan, during an outbreak in 2022-2023

Haider,

Jamal,

Tahir

et al. 2024

Arch Virol

View full text Add to dashboard Cite

Analysis of respiratory syncytial virus fusion protein from clinical isolates of Korean children in palivizumab era, 2009–2015

Cited by 6 publications

References 26 publications

Genotype Analysis of Respiratory Syncytial Virus Before and After the COVID-19 Pandemic Using Whole-Genome Sequencing: A Prospective, Single-Center Study in Korea From 2019 to 2022

Genotype Analysis of Respiratory Syncytial Virus Before and After the COVID-19 Pandemic Using Whole-Genome Sequencing: A Prospective, Single-Center Study in Korea From 2019 to 2022

Clinical and biological consequences of respiratory syncytial virus genetic diversity

Genomic characterization of human respiratory syncytial virus circulating in Islamabad, Pakistan, during an outbreak in 2022-2023

Contact Info

Product

Resources

About